CMS discusses VBP's effects on Medicaid best price

In new guidance discussing the effects of future value-based pricing (VBP) arrangements on Medicaid best prices, CMS encouraged states and manufacturers to negotiate CMS-approved supplemental rebates that would be excluded from Medicaid best price.

Last month, Massachusetts' state Medicaid program said drug makers Gilead Sciences inc. (NASDAQ:GILD) and Bristol-Myers Squibb Co. (NYSE:BMY) would provide supplemental rebates to broaden access to HCV drugs. CMS acting Administrator Andy Slavitt endorsed the negotiations (see BioCentury Extra, July 1)...